• Avita Medical disclosed positive results from the PermeaDerm-I randomized study in burn care.
• Findings were scheduled for review in a Key Opinion Leader webinar at 4:30 p.m. ET on Aug. 18, 2026.
• PermeaDerm showed comparable patient outcomes versus cadaveric allograft in temporary wound coverage.
• Product economics favored PermeaDerm, positioning it as a lower-cost alternative for hospitals.
• Workflow benefits improved versus allograft, supporting an off-the-shelf option with fewer preparation and logistics steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avita Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608180745PRIMZONEFULLFEED9811808) on August 18, 2026, and is solely responsible for the information contained therein.